Skip to content
Menu

Opus Genetics Doses First Participant In Phase 1/2 Clinical Trial Evaluating Opgx-RDH12, Investigational Gene Therapy For RDH12-LCA, Rare Inherited Retinal Disease

Benzinga Newsdesk 12 hours ago

News

First participant dosed with OPGx-RDH12, an investigational gene therapy designed to address the underlying genetic cause of RDH12-associated Leber congenital amaurosis (RDH12-LCA)Milestone advances Opus Genetics'

First participant dosed with OPGx-RDH12, an investigational gene therapy designed to address the underlying genetic cause of RDH12-associated Leber congenital amaurosis (RDH12-LCA)

Milestone advances Opus Genetics' third gene therapy program into clinical development, following FDA clearance of its Investigational New Drug application in October 2026

Clinical program supported by strategic collaboration with the Global RDH12 Alliance, bringing together patient advocacy organizations RDH12 Fund for Sight and Eyes on the Future

RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the first participant has been dosed in its Phase 1/2 clinical trial evaluating OPGx-RDH12, an investigational gene therapy for RDH12-associated Leber congenital amaurosis (RDH12-LCA), a rare inherited retinal disease that causes progressive vision loss and blindness beginning in early childhood and affects approximately 2,500 individuals in the U.S.

The milestone follows U.S. Food and Drug Administration (FDA) clearance of the Company's Investigational New Drug (IND) application in October 2026 and marks the advancement of Opus Genetics' third gene therapy program into clinical development.

OPGx-RDH12 is designed to deliver a functional copy of the RDH12 gene directly to photoreceptor cells in the retina, with the goal of preserving retinal function and vision. The Phase 1/2 clinical trial will evaluate the safety and tolerability of OPGx-RDH12, along with exploratory measures of retinal structure and visual function.

Read at benzinga.com